InnoCan Pharma Corporation
INNO
CNSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 48.19% | -37.04% | -18.57% | -24.87% | -60.56% |
| Total Depreciation and Amortization | -2.63% | 12.12% | 24.14% | -5.71% | 8.57% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1.77% | 617.43% | 391.81% | 186.11% | 151.47% |
| Change in Net Operating Assets | -112.67% | 47.03% | -268.44% | -49.34% | -31.76% |
| Cash from Operations | 39.70% | 54.31% | 38.26% | 35.65% | 43.91% |
| Capital Expenditure | 58.33% | 72.55% | 50.00% | -76.92% | -220.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 100.00% | -190.91% | -158.33% | -660.00% | -514.29% |
| Cash from Investing | 78.02% | 25.81% | 3.70% | -170.97% | -313.64% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -10.53% | -100.00% | -950.00% | -100.00% | -5.56% |
| Issuance of Common Stock | 64.57% | 514.06% | 474.56% | 1,043.38% | -76.70% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 118.34% | 1,241.56% | 1,241.56% | -- | -75.34% |
| Cash from Financing | 90.43% | 764.44% | 711.74% | 2,233.60% | -76.28% |
| Foreign Exchange rate Adjustments | 112.06% | 69.43% | 114.98% | 107.03% | -376.47% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 143.19% | 141.72% | 109.27% | 82.59% | -534.91% |
